We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Airway Redox and Gender Determinants in Severe Asthma (SARP3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01759186
Recruitment Status : Active, not recruiting
First Posted : January 3, 2013
Last Update Posted : July 18, 2017
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The investigators will study the biologic and chemical differences that cause the greater incidence, and severity of asthma in women as compared to men. Severe asthma affects boys more than girls, while severe asthma in adults is predominantly a disease of women. The investigators aim to identify the processes that occur in the body that are behind the onset of severe asthma in young women during the teenage years, and the resolution of severe asthma in boys. To further evaluate gender influences on asthma, asthmatic women at different stages of their menstrual cycle (period) will be also studied. The investigators aim to use biomarkers to develop testing procedures that will identify different types or characteristics of asthma in men and women; and to follow patients over time to uncover relevant clinical outcomes of biomarkers. The investigators anticipate that they will 1) develop clinically relevant tests to identify unique types or characteristics of asthma and severe asthma; 2) determine outcomes over time of biochemically-defined types of asthma; and 3) identify the reasons for why adult women are affected more than men with severe asthma.

Condition or disease
Asthma

Detailed Description:
This scientific site-specific project is part of a larger network of asthma studies, the Severe Asthma Research Program (SARP). The mission of SARP is to improve the understanding of severe asthma to develop better treatments.

Study Design

Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Severe Asthma Research Program
Study Start Date : December 2012
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Groups and Cohorts

Group/Cohort
None interventional


Outcome Measures

Primary Outcome Measures :
  1. Identify metabolic mechanism(s) and age dependent change in the epidemiology of asthma [ Time Frame: 5 years ]
    To determine if asthma severity is worsened in females with changes in estradiol that occur during puberty as measured by asthma control tests and lung functions


Secondary Outcome Measures :
  1. Development of clinical testing procedures to assign metabolic asthma phenotypes [ Time Frame: 5 years ]
    To determine if urine and blood and exhaled metabolic biomarkers can predict asthma phenotypes and severity as measured by lung functions and asthma control tests


Other Outcome Measures:
  1. Gender influences on severe asthma [ Time Frame: 5 years ]
    To determine if adult women have more severe asthma in relation to menstrual cycle as measured by lung functions and remodeling on biopsies of the airway.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients living in the greater Cleveland area, and in Virginia
Criteria

Inclusion Criteria:

Subjects with asthma

  • children age 6-17 years old (25% enrollment)
  • adults 18 years and older (75% enrollment)

Exclusion Criteria:

  • Pregnancy during the characterization phase
  • Current smoking
  • Smoking history > 10 pack years if ≥30 years of age, or smoking history > 5 pack years if <30 years of age (Note: if a subject has a smoking history, no smoking within the past year),
  • Other chronic pulmonary disorders associated with asthma-like symptoms, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion)
  • Severe scoliosis or chest wall deformities
  • History of premature birth before 35 weeks gestation
  • Unwillingness to receive an intramuscular triamcinolone acetonide injection.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01759186


Locations
United States, Ohio
Rainbow Babies and Children's Hospital
Cleveland, Ohio, United States, 44106
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
The Cleveland Clinic
Case Western Reserve University
University of Virginia
Investigators
Principal Investigator: Serpil C Erzurum, MD The Cleveland Clinic
Principal Investigator: Benjamin Gaston, MD Case Western Reserve University
Principal Investigator: W. Gerald Teague, MD University of Virginia
More Information

Responsible Party: Serpil Erzurum, multiple Prinicipal Investigators [B Gaston, S. Erzurum, G. Teague], The Cleveland Clinic
ClinicalTrials.gov Identifier: NCT01759186     History of Changes
Other Study ID Numbers: 6185
First Posted: January 3, 2013    Key Record Dates
Last Update Posted: July 18, 2017
Last Verified: July 2017

Keywords provided by Serpil Erzurum, The Cleveland Clinic:
Asthma
Biomakers
Phenotype

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases